Relay Therapeutics, Inc. (RLAY)
Market Cap | 2.59B |
Revenue (ttm) | 1.70M |
Net Income (ttm) | -290.46M |
Shares Out | 120.90M |
EPS (ttm) | -2.66 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 84,267 |
Open | 21.39 |
Previous Close | 21.46 |
Day's Range | 21.14 - 21.78 |
52-Week Range | 12.65 - 35.36 |
Beta | 1.01 |
Analysts | Buy |
Price Target | 37.94 (+76.79%) |
Earnings Date | Feb 22, 2023 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit... [Read more]
Financial Performance
In 2021, RLAY's revenue was $3.03 million, a decrease of -96.34% compared to the previous year's $82.65 million. Losses were -$363.87 million, 58.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is $37.94, which is an increase of 76.79% from the latest price.
News

Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p...

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision Onc...

Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

Relay Therapeutics (NASDAQ:RLAY) – Why Relay Therapeutics Shares Are Getting Hammered
Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per ...

Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay's Investigational FGFR2 Inhibitor, RLY-4008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company tran...

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (...

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference o...

Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at...
Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says
Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast canc...

Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
EMERYVILLE, Calif.--(BUSINESS WIRE)--Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, a...